Noncompliance with antihypertensive therapy. Economic consequences.

Suppr

超能文献

作者信息

Skaer T L, Sclar D A, Robison L M

机构信息

College of Pharmacy, Washington State University, Pullman, USA.

出版信息

Pharmacoeconomics. 1996 Jan;9(1):1-4. doi: 10.2165/00019053-199609010-00001.

DOI:10.2165/00019053-199609010-00001

PMID:10160083

Abstract

摘要

相似文献

Noncompliance with antihypertensive therapy. Economic consequences.

Pharmacoeconomics. 1996 Jan;9(1):1-4. doi: 10.2165/00019053-199609010-00001.

Hypertension and current issues in compliance and patient outcomes.高血压以及依从性和患者预后方面的当前问题。

Curr Hypertens Rep. 2000 Dec;2(6):510-4. doi: 10.1007/s11906-996-0034-7.

Some economic consequences of noncompliance.

Curr Hypertens Rep. 2001 Dec;3(6):473-80. doi: 10.1007/s11906-001-0009-7.

Compliance, quality of life, and cost effectiveness.依从性、生活质量和成本效益。

Curr Hypertens Rep. 1999 Dec;1(6):471-4. doi: 10.1007/s11906-996-0017-8.

Time to patient discontinuation of antihypertensive drugs in different classes.

Am J Health Syst Pharm. 2000 Jan 1;57(1):51-4. doi: 10.1093/ajhp/57.1.51.

Compliance with antihypertensive therapy: raising the bar of expectations.抗高血压治疗的依从性：提高期望标准。

Am J Manag Care. 1998 Jul;4(7):957-66.

[Pharmacoeconomic analysis of antihypertensive therapy: advantages of fixed combinations].抗高血压治疗的药物经济学分析：固定复方制剂的优势

Kardiologiia. 2008;48(1):43-50.

Are there unintended consequences of step-therapy programs?阶梯治疗方案是否存在意外后果？

Am J Manag Care. 2009 Sep;15(9):654, 656; author reply 656.

Pharmacist-led hypertension disease management program cuts utilization and costs.

Healthc Demand Dis Manag. 1997 Dec;3(12):191-2.

Approach to polypharmacy.

J Am Board Fam Pract. 1998 Jul-Aug;11(4):331-2. doi: 10.3122/jabfm.11.4.331a.

引用本文的文献

Discontinuation of anti-hypertensive drugs increases 11-year cardiovascular mortality risk in community-dwelling elderly (the Bambuí Cohort Study of Ageing).停用降压药会增加社区老年居民11年心血管疾病死亡风险（班布伊衰老队列研究）。

BMC Public Health. 2014 Jul 16;14:725. doi: 10.1186/1471-2458-14-725.

The role of religion in relation to blood pressure control among a Southern California Thai population with hypertension.宗教在南加州高血压泰裔人群血压控制方面的作用。

J Relig Health. 2012 Mar;51(1):187-97. doi: 10.1007/s10943-010-9341-z.

Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.抗高血压药物治疗评估中的血压降低、持续性及成本——综述

Cardiovasc Diabetol. 2009 Mar 27;8:18. doi: 10.1186/1475-2840-8-18.

The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review.心血管疾病及相关病症中不依从治疗的经济后果：一项文献综述

Int J Clin Pract. 2008 Feb;62(2):338-51. doi: 10.1111/j.1742-1241.2007.01683.x.

Pharmacoeconomic burden of undertreating hypertension.高血压治疗不足的药物经济学负担

Pharmacoeconomics. 2004;22(14):907-28. doi: 10.2165/00019053-200422140-00002.

Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies.抗高血压药物治疗的药物经济学：关于患者接受各种抗高血压治疗的时长分析。

J Clin Hypertens (Greenwich). 2004 Feb;6(2):76-84. doi: 10.1111/j.1524-6175.2004.03044.x.

Pharmacoeconomics of hypertension management: the place of combination therapy.高血压管理的药物经济学：联合治疗的地位

Pharmacoeconomics. 2001;19(4):337-47. doi: 10.2165/00019053-200119040-00002.

[Socioeconomic and quality of life repercussions of arterial hypertension].[动脉高血压对社会经济和生活质量的影响]

Drugs. 1998;56 Suppl 2:45-53. doi: 10.2165/00003495-199856002-00005.

本文引用的文献

Patient-focused care from the consultant's viewpoint: we didn't plan it this way.从顾问角度看以患者为中心的护理：我们并非有意如此安排。

Am J Health Syst Pharm. 1995 Jan 1;52(1):45-8. doi: 10.1093/ajhp/52.1.45.

Translating safety, efficacy and compliance into economic value for controlled release dosage forms.将控释剂型的安全性、有效性和依从性转化为经济价值。

Pharmacoeconomics. 1994 Jun;5(6):482-504. doi: 10.2165/00019053-199405060-00005.

Pharmaceutical formulation and healthcare expenditures.药物制剂与医疗保健支出。

Pharmacoeconomics. 1992 Oct;2(4):267-9. doi: 10.2165/00019053-199202040-00002.

Pharmacoeconomic series: Part 3. Applying pharmacoeconomic and quality-of-life measures to the formulary management process.药物经济学系列：第3部分。将药物经济学和生活质量指标应用于处方集管理过程。

Hosp Formul. 1993 Jun;28(6):577-84.

Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society.原发性高血压管理指南：英国高血压学会第二工作组报告

BMJ. 1993 Apr 10;306(6883):983-7. doi: 10.1136/bmj.306.6883.983.

Antihypertensive therapy--efficacy and quality of life.抗高血压治疗——疗效与生活质量。

N Engl J Med. 1993 Apr 1;328(13):959-61. doi: 10.1056/NEJM199304013281311.

Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group.男性的生活质量与抗高血压治疗。卡托普利与依那普利的比较。生活质量高血压研究组。

N Engl J Med. 1993 Apr 1;328(13):907-13. doi: 10.1056/NEJM199304013281302.

Blood pressure, systolic and diastolic, and cardiovascular risks. US population data.收缩压和舒张压以及心血管风险。美国人口数据。

Arch Intern Med. 1993 Mar 8;153(5):598-615. doi: 10.1001/archinte.153.5.598.

Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease.近期关于轻度至中度高血压药物治疗及冠心病风险降低的证据。

Arch Intern Med. 1993 Mar 8;153(5):578-81.

The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V).全国高血压检测、评估与治疗联合委员会第五次报告（JNC V）

Arch Intern Med. 1993 Jan 25;153(2):154-83.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验